Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular and Cellular Mechanism during Immunotherapy with Phleum pratense Oral Lyophilisate (Grazax)
2012-005092-14Phase 4Completed
- Sponsor
- ALK-Abelló
- Start
- Jan 2013
- Countries
- 1
01
Overview
Phase 4, single-arm trial of phleum pratense allergen extract in allergic rhinitis (AR) and allergic conjunctivitis (AC), sponsored by ALK-Abelló. Primary endpoint: Immunological markers over course of treatment. Started Jan 2013; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2012-005092-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005092-14.